A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly half-a-billion-dollar investment from Italian drugmaker Chiesi. As part of an ongoing ...

Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers 1, ensuring patients ...

Findings showed BDP/FF/G improved predose FEV1 and reduced the rate of moderate to severe exacerbations compared with BDP/FF. The Food and Drug Administration (FDA) has accepted for review the New ...

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S.

Chiesi Group (Chiesi), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, ...